Israel maintained its position as one of the world’s most productive centers of biomedical research and clinical translation throughout the first half of 2026 and the opening months of the second half.
With a dense concentration of research universities, teaching hospitals, and biotechnology companies, the country continued to generate discoveries that move rapidly from laboratory insight to preclinical validation and, in several cases, first-in-human application.
The period was marked by notable progress in gene therapy for rare neurological diseases, novel approaches to cancer immunotherapy and microenvironment modulation, regenerative strategies for diabetes, advanced diagnostics, and the integration of artificial intelligence into clinical decision-making.
Many of these advances were published in leading peer-reviewed journals or advanced into regulated clinical trials, underscoring the resilience and scientific depth of Israel’s medical research ecosystem.
Gene Therapy and Neurological Medicine
A defining clinical milestone of 2026 occurred in June at Clalit–Schneider Children’s Medical Center. An eight-month-old infant diagnosed with WWOX-related epileptic encephalopathy (WOREE syndrome) became the first patient worldwide to receive an experimental gene-replacement therapy delivered directly into the brain.
WOREE syndrome is a severe, ultra-rare genetic disorder caused by loss-of-function mutations in the WWOX gene. It presents with early-onset, drug-resistant epilepsy, profound developmental delay, and a high risk of premature death. Conventional anticonvulsants and supportive care offer little disease-modifying benefit.
The therapeutic approach was grounded in more than a decade of research led by Professor Rami Aqeilan at the Lautenberg Center for Immunology and Cancer Research, Faculty of Medicine, Hebrew University of Jerusalem. Aqeilan’s laboratory had previously established the critical role of WWOX in brain development and neuronal function. The experimental therapy employed a specially engineered adeno-associated viral vector carrying a functional copy of the human WWOX gene.
Under a carefully coordinated compassionate-use framework that involved Israeli clinicians, an Arab geneticist, and biotechnology partners, neurosurgeons injected the vector into the infant’s brain. One month after the procedure the child remained clinically stable and was discharged.
The case represents both a technical and ethical landmark: it demonstrated the feasibility of direct central-nervous-system gene delivery for a previously untreatable monogenic epilepsy and provided a foundation for subsequent formal clinical development programs.
Complementing this achievement, researchers at the Hebrew University of Jerusalem’s School of Pharmacy, led by Professor Tawfeeq Shekh-Ahmed, published preclinical data on an activity-responsive gene therapy designed for epilepsy. The system incorporates a genetic switch that remains largely inactive under normal neuronal conditions and becomes activated only when neurons enter a hyperactive state characteristic of seizures.
The molecular architecture combines elements of the Nrf2 protective pathway with the cfos promoter, which is rapidly induced by intense neuronal firing. In animal models the therapy reduced seizure severity and frequency, extended seizure-free intervals, and produced measurable improvements in memory, behavior, and overall brain function.
Importantly, efficacy was retained even in models of long-standing, drug-resistant epilepsy. The conceptual advance is significant: rather than imposing continuous pharmacological suppression, the treatment intervenes selectively and dynamically, potentially limiting cumulative side effects and disease progression.
Progress in Alzheimer’s disease research also reached a clinical inflection point. Professor Michal Schwartz of the Weizmann Institute of Science has long argued that age-related decline in peripheral immune surveillance contributes to the inability of the brain to clear pathological proteins and resolve chronic neuroinflammation.
Building on this framework, the company ImmunoBrain developed IBC-Ab002, a short-lived humanized anti-PD-L1 antibody engineered specifically for neurodegenerative rather than oncological indications. Results of a multicenter Phase 1b trial involving 40 patients with early-stage Alzheimer’s disease were published in Nature Medicine.
The study, conducted at sites in Israel, the United Kingdom, and the Netherlands, demonstrated that the antibody was safe and well tolerated across ascending dose levels. Exploratory analyses revealed reductions in cerebrospinal-fluid biomarkers associated with neuronal injury and synaptic dysfunction. Although Phase 1 trials are not powered for efficacy, the safety profile and biomarker signals support continued clinical development of an immune-restoration strategy that differs fundamentally from amyloid-directed approaches.
Additional neurological advances included a Tel Aviv University therapy that lowers extracellular glutamate after spinal cord injury through a simple intravenous route. Excess glutamate drives secondary neuronal death and inflammation. In animal models the treatment preserved axonal and synaptic architecture and enabled recovery of up to 80 percent of normal motor function within two months, compared with approximately 30 percent in untreated controls.
The therapeutic window extended to at least eight hours after injury, a clinically relevant interval. Parallel work at Tel Aviv University identified a previously underappreciated biological mechanism that may permit regeneration of sensory hair cells in the mammalian inner ear—cells long considered post-mitotic and non-regenerative in humans. While still at an early mechanistic stage, the findings open a conceptual path toward regenerative therapies for irreversible sensorineural hearing loss.
Sheba Medical Center reported the successful development and application of Israel’s first fully patient-specific antisense oligonucleotide therapy for a child with GNAO1-related neurodevelopmental disorder, further illustrating the growing capacity of Israeli centers to design individualized genetic interventions for rare diseases.
Oncology: Fundamental Insights and Translational Progress
Oncology research in 2026 yielded both conceptual advances and concrete clinical programs. At the Weizmann Institute of Science, Professor Ziv Shulman’s laboratory examined lymph-node tissue from patients with high-grade serous ovarian carcinoma. Contrary to prevailing expectations focused almost exclusively on T-cell immunity, the team demonstrated that memory B cells can directly recognize and attack ovarian cancer cells by producing antibodies with high specificity for tumor-associated antigens.
Published in the journal Immunity, the work showed that a substantial fraction of these antibodies bound preferentially to malignant cells and that the B-cell compartment retained immunological memory capable of rapid recall responses. The findings suggest that therapeutic vaccines or monoclonal antibodies derived from such B-cell responses could help prevent the high rate of relapse that characterizes ovarian cancer after surgery and chemotherapy.
A distinct approach emerged from the Technion–Israel Institute of Technology. Researchers led by Assistant Professor Assaf Zinger engineered biomimetic nanoparticles, termed MPsomes, that carry no chemotherapeutic or biological payload. Instead, the particles incorporate proteins from macrophage membranes and thereby interfere with the recruitment of tumor-associated macrophages that support an immunosuppressive microenvironment.
In preclinical models of triple-negative breast cancer—one of the most aggressive and treatment-resistant subtypes—the nanoparticles accumulated preferentially at the tumor site and inhibited growth with efficacy comparable to approved anti-PD-1 immunotherapy.
Results published in ACS Nano highlighted both the therapeutic effect and practical advantages: the particles are manufactured from materials already recognized as safe by regulatory agencies, and production rates are compatible with clinical-scale needs. The work exemplifies a growing interest in microenvironment modulation rather than direct cytotoxicity.
Complementing these laboratory advances, a Technion artificial-intelligence model trained on routine histopathological images was shown to predict both recurrence risk and the likelihood of benefit from adjuvant chemotherapy in breast cancer. Validated against data from a large randomized clinical trial and reported in The Lancet Oncology, the system performed consistently across institutions and imaging conditions. If further confirmed, such tools could reduce dependence on expensive genomic assays while supporting more individualized treatment decisions.
In July 2026, Silexion Therapeutics initiated a Phase 2/3 clinical trial of its second-generation small interfering RNA candidate SIL204 at Tel Aviv Sourasky Medical Center. SIL204 is designed to silence mutated KRAS genes, which drive approximately 90 percent of pancreatic cancers.
The trial employs a dual-route administration strategy—intratumoral injection to overcome the dense stromal barrier of pancreatic tumors combined with systemic delivery to address micrometastatic disease—administered together with standard chemotherapy. The initial safety run-in cohort is expected to enroll approximately 18 patients before expansion. The program represents the first clinical evaluation of this specific siRNA approach for locally advanced pancreatic cancer and reflects Israel’s growing contribution to RNA-based oncology therapeutics.
Diagnostic innovation also advanced. Researchers at Tel Aviv University, led by Professor Yuval Ebenstein, developed a blood test that detects lung cancer by optically reading methylation patterns on cell-free DNA without the need for next-generation sequencing.
In a study of more than 100 participants published in npj Precision Oncology, the assay achieved 93.1 percent sensitivity and 90.3 percent specificity for stage 2–4 disease. The test can be completed in two to three days at a cost of approximately sixty dollars, positioning it as a potentially accessible complement to low-dose computed tomography for screening and treatment monitoring.
Regenerative Medicine and Metabolic Disease
A major contribution to regenerative medicine came from collaborative work led by Assistant Professor Shady Farah of the Technion in partnership with investigators at MIT, Harvard, Johns Hopkins, and other institutions. The team created a living, cell-based implant intended to function as an autonomous artificial pancreas.
Therapeutic cells within the implant continuously sense glucose concentrations, synthesize insulin, and release it in a regulated manner. The critical enabling technology is a crystalline shield that protects the allogeneic cells from immune recognition and rejection, allowing long-term function without systemic immunosuppression.
Successful glucose regulation in murine models and viability studies in non-human primates were reported in Science Translational Medicine. If translated successfully to humans, the platform could eliminate the need for daily insulin injections and continuous glucose monitoring for many patients with diabetes, while offering a modular architecture adaptable to other chronic conditions requiring sustained biological delivery.
Hebrew University researchers further advanced the concept of programmable mammalian cells capable of integrating multiple environmental signals and executing logical therapeutic responses. One demonstration involved engineered cells that produce the cytokine interleukin-15 only under defined conditions, thereby enhancing local anti-tumor immunity while limiting systemic exposure. Such systems point toward a future generation of context-aware living therapeutics.
Clinical Technology and Hospital-Based Innovation
Israeli medical centers continued to integrate engineering and computational tools into routine care. Rambam Health Care Campus deployed artificial-intelligence clinical decision-support systems in both adult and pediatric emergency departments to accelerate recognition of complex or atypical presentations and to reduce diagnostic delays. The same institution advanced programs in patient-specific metal 3D-printed implants and biological cartilage repair using coral-derived scaffolds.
Shaare Zedek Medical Center introduced reversible electroporation combined with bleomycin for complex vascular malformations, particularly in children and adolescents. The technique transiently permeabilizes cell membranes, allowing extremely high local drug concentrations and reducing the number of invasive procedures required.
Ecosystem Resilience and Broader Context
The scientific output of 2026 occurred against a background of significant external pressure. Certain research facilities, including buildings at the Weizmann Institute, had sustained damage in prior attacks, yet laboratories continued to publish high-impact work. The combination of strong basic science, efficient technology-transfer mechanisms, and a culture of rapid clinical translation continues to distinguish the Israeli biomedical landscape.
Outlook for the Remainder of 2026 and Beyond
Several programs initiated or advanced in the first half of the year are expected to generate additional data in the coming months. The Silexion pancreatic cancer trial will report early safety and pharmacokinetic observations. Further clinical experience with the Alzheimer’s immune-modulating antibody and continued development of the living pancreas implant are anticipated. Diagnostic tools such as the methylation-based lung-cancer blood test are entering expanded validation studies. Collectively, these efforts reinforce Israel’s contribution to global pipelines in gene therapy, oncology, regenerative medicine, and precision diagnostics.
The advances of 2026 illustrate a consistent pattern: deep mechanistic insight, willingness to pursue unconventional therapeutic strategies, and a capacity to move promising concepts into clinical evaluation with relative speed. While many of the reported technologies remain in early stages and require rigorous confirmation in larger trials, the overall trajectory positions Israeli research as a continuing source of innovation with potential benefit far beyond national borders.
Tools used for research, translation, proof reading, verification of codes/equations, pic generation etc.: LLMs / SE / BusinessSoftware / Parsers / DB/ Websites etc. All articles: Creative Commons BY-NC-ND 4.0 (Attribution-NonCommercial-NoDerivs) hold by Dr. Naftali Hirschl. Pic by AI (illustrative). No warranty.